



ASX/media release

9 October 2007

### Placement of Colonial's AtCor shares oversubscribed

AtCor Medical Holdings Limited (ASX:ACG), has been advised by Colonial First State Global Asset Management that the shareholdings in AtCor held by H-G Fund No 5 and the Diversified Private Equity Fund have been placed with Australian and US investors. Colonial First State has previously disclosed that it will not directly be raising further private equity funds and that both these funds are realising their assets. The placement, which represents 26.5 per cent of AtCor's issued capital, was oversubscribed.

AtCor directors and employees have agreed to take up 3.3 million of the shares, representing 12.7 per cent of the total placement.

H-G Fund No 5 was AtCor's initial external investor, providing venture capital for the company in 1998. Subsequently, Colonial First State Diversified Private Equity Fund provided additional capital prior to AtCor's ASX listing in November 2005. Both shareholdings were in voluntary escrow until November 2007 and the underwriter to AtCor's initial public offering has agreed to the early release.

Duncan Ross, CEO of AtCor, said: 'It has been apparent for some time that Colonial First State's shares in AtCor would be sold. The placement of the shares with existing and new investors and with AtCor directors and employees will remove this 'overhang' from the market and broaden the company's share register. It will also be an important step towards achieving a valuation for the company that reflects the fundamentals of our business.'

Donal O'Dwyer, Chairman of AtCor, commented: 'The decision of AtCor directors and employees to take up shares in the placement is a powerful sign of their confidence in the outlook for the company. AtCor's SphygmoCor technology is the first to measure blood pressure at the heart non-invasively, and there is strong evidence among medical practitioners that central blood pressure is vitally important in diagnosing and managing cardiovascular disease. Orders for the SphygmoCor system during FY2007 were 86 per cent above FY2006. With our world-class team, we are well positioned to build on this momentum.'

#### **About AtCor**

AtCor Medical develops and markets products for the early detection and management of cardiovascular disease. More than 1,000 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. AtCor has operations in Australia, the United States, and Europe. AtCor is listed on the ASX under code ACG. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact:*

*Media enquiries to:*

Duncan Ross – AtCor Medical CEO  
+1 (630) 799 8221

Ashley Rambukwella – Financial & Corporate  
Relations

Peter Manley – AtCor Medical CFO  
+61 (2) 9874 8761

Ph: +61 (2) 8264 1004/ m. 0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)